Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02990819 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2025 to Nov 2026
    • Study completion date: Dec 2026 to Dec 2027
    v15
  2. Primary completion date: Feb 2025 to Oct 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2025 to Dec 2026
    • Site details revised
    v14
  3. Site contact updatedv13
  4. Site contact updatedv12
  5. Primary completion date: Jan 2024 to Feb 2025
    • Study completion date: Jan 2024 to Dec 2025
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary and study completion dates: Dec 2023 to Jan 2024v10
  2. Enrollment target: 50 to 60
    • Site contact updated
    v9
  3. Collaborators shortened, about 5 wordsv8
  4. Enrollment target: 40 to 50v7
  5. Eligibility criteria expanded, about 18 words
    • Site contact updated
    • Study description expanded, about 2 words
    v6
  6. Enrollment target: 25 to 40v5
  7. Re-verified, no change to tracked fieldsv4
  8. Eligibility criteria revised
    • Study description expanded, about 19 words
    • Study arms: 2 to 3
    • Collaborators expanded, about 5 words
    v3
  9. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with alpha/beta T and CD19+ depleted peripheral stem cell grafts from unrelated or partially matched related donors. There are two conditioning regimens depending upon patient diagnosis and age.
Trial Details
NCT Number NCT02990819
Lead Sponsor Children's Hospital of Philadelphia
Conditions
(from sponsor)		 Immunodeficiencies, Immune Dysregulation Syndromes
Related terms Immunologic Deficiency Syndromes
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov